SHORT-TERM INTRAHEPATIC FUDR INFUSION COMBINED WITH BOLUS MITOMYCIN-C - REDUCED RISK FOR DEVELOPING DRUG-RESISTANCE

被引:4
作者
ARISAWA, Y [1 ]
SUTANTOWARD, E [1 ]
DALTON, RR [1 ]
SIGURDSON, ER [1 ]
机构
[1] FOX CHASE CANC CTR, DEPT SURG, SURG ONCOL LAB, 7701 BURHOLME AVE, PHILADELPHIA, PA 19111 USA
关键词
COLORECTAL CANCER; HEPATIC METASTASES; ANIMAL MODEL; DRUG COMBINATION; HEPATIC ARTERIAL CHEMOTHERAPY; CHEMOSENSITIVITY;
D O I
10.1002/jso.2930560205
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluates tumor response, survival, and development of resistance to HAI chemotherapy, comparing a combination of bolus MMC and short duration FUdR to short duration FUdR alone or to long duration FUdR alone, using a rat hepatic metastases model. After intrasplenic injection of 10(7) K12/TRb colon cancer cells in BD-IX rats on day 0, hepatic metastases were evaluated and HA catheters were placed on day 14. The response was determined on day 28. Chemosensitivity of the hepatic metastases after HAI treatments was determined using the MTT assay. Bolus MMC with short duration FUdR as well as long-term FUdR alone provided better hepatic tumor response and survival than short-term FUdR alone. However, bolus MMC with short duration FUdR decreased the acquired resistance to FUdR, compared to long-term FUdR, without causing resistance to MMC. These results provide a rationale for using short duration of FUdR in combination with other drugs. (C) 1994 Wiley-Liss, Inc.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 26 条
[1]  
COSIMELLI M, 1991, J SURG ONCOL, P63
[2]   CLINICAL USEFULNESS OF CHEMOSENSITIVITY TESTING USING THE MTT ASSAY [J].
FURUKAWA, T ;
KUBOTA, T ;
SUTO, A ;
TAKAHARA, T ;
YAMAGUCHI, H ;
TAKEUCHI, T ;
KASE, S ;
KODAIRA, S ;
ISHIBIKI, K ;
KITAJIMA, M .
JOURNAL OF SURGICAL ONCOLOGY, 1991, 48 (03) :188-193
[3]  
HEGGIE GD, 1987, CANCER RES, V47, P2203
[4]  
HOHN DC, 1986, CANCER, V57, P465, DOI 10.1002/1097-0142(19860201)57:3<465::AID-CNCR2820570311>3.0.CO
[5]  
2-S
[6]   A RANDOMIZED TRIAL OF CONTINUOUS INTRAVENOUS VERSUS HEPATIC INTRAARTERIAL FLOXURIDINE IN PATIENTS WITH COLORECTAL-CANCER METASTATIC TO THE LIVER - THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP-TRIAL [J].
HOHN, DC ;
STAGG, RJ ;
FRIEDMAN, MA ;
HANNIGAN, JF ;
RAYNER, A ;
IGNOFFO, RJ ;
ACORD, P ;
LEWIS, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1646-1654
[7]   RANDOMIZED TRIAL OF HEPATIC ARTERIAL FLOXURIDINE, MITOMYCIN, AND CARMUSTINE VERSUS FLOXURIDINE ALONE IN PREVIOUSLY TREATED PATIENTS WITH LIVER METASTASES FROM COLORECTAL-CANCER [J].
KEMENY, N ;
COHEN, A ;
SEITER, K ;
CONTI, JA ;
SIGURDSON, ER ;
TAO, Y ;
NIEDZWIECKI, D ;
BOTET, J ;
BUDD, A .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :330-335
[8]  
KEMENY N, 1992, CANCER, V69, P327, DOI 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO
[9]  
2-U
[10]  
KEMENY N, 1992, SEMIN ONCOL, V19, P155